How We Help
Strategic Launch Report and Evaluate Forecast can help commercial teams produce more accurate forecasts of launch activity, even in new indications and those with a lot of pipeline and/or competitive activity and limited payer coverage.
Highlight potential obstacles from new drug launch policies.
Correlate analogs’ policy uptake with sales volumes to get a complete picture and set realistic launch expectations.
Identify scenarios when agents with more restrictive or slow policy uptake still experienced sales uptake or vice versa.
Through color commentary from Evaluate and MMIT syndicated reports, understand the reasoning behind what payer did vs. what physicians did.